Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery

NCT ID: NCT02539693

Last Updated: 2022-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sacrococcygeal local anesthesia was shown to reduce the time spent in the operating room as well as in the recovery room. In addition, decreased hospital stay and postoperative analgesic consumption.

Given the effectiveness of sacrococcygeal local anesthesia in pilonidal sinus surgery, it would be valuable to study the effect of the local anesthesia with 75µg/mL of clonidine versus 150µg/mL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design and sampling

This is a prospective study with a randomized double-blind design that will be conducted between October 2015 and October 2016.

Patients scheduled for pilonidal sinus surgery will be included. Patients will be randomly distributed to one of 2 groups with 30 patients in each, using the sealed envelope technique. Group one will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine, while group two will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine.

Anesthetic techniques

Being a double-blinded study, a specialized nurse will prepare the syringes for each patient.

Sacrococcygeal local anesthesia technique

The Sacrococcygeal block will be performed with the patient in the prone position. Four injection sites are marked on the skin after aseptic preparation.

The sites are placed as follows: 4 cm below and above the pilonidal sinus and 3 cm lateral to its center on both sides. Therefore a "lozenge" is formed by connecting the 4 sites.

At first, an injection of 0.3 ml lidocaine 1% is injected at each site using an 8-mm 30G needle. Then 4 injections are admitted to each of the 4 injection sites in turn, with equal supply of the anesthetic mixture in the following manner: a 10-mm 27G needle containing the anesthetic mixture is introduced perpendicularly to the skin and the mixture is infiltrated. The needle is partially withdrawn and reinserted at 45 degrees to the skin aiming towards the center of the pilonidal sinus and an injection will be performed. Then the needle is partially withdrawn again and reinserted at an angle of 45 degrees to the skin aiming at one side of the lozenge then at the other side where injections are done.

In case of a multiple pilonidal orifices, a hexagon is done. These sites are then anesthetized as previously described.

Anesthetic mixture

For group 1, the syringe will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).

As for group 2, the syringes will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).

Depending on each patient's weight and type of pilonidal sinus, the anesthetic mixture might vary from 30 to 40 mL in total.

Data collection

Demographic data, type and duration of surgery will be recorded. Haemodynamics will be registered at all times (pre-operatively, intra-operatively and post-operatively).

Pain will be assessed using VNRS with 0 being no pain and 10 maximum pain for 48 hours post-operatively.

As for postoperative analgesia consumption, patients with a VNRS score less than 3 are given paracetamol 1000 mg each 8 hours. If VNRS is between three and four, patients are given Tramadol Hydrochloride 50-100 mg every 4- 6 hours and if the VNRS score is greater or equal to five, patients receive 1 mg/kg Dolosal.

Return to normal activity will be defined by the ability to sit, walk and work comfortably and will be assessed by calling the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pilonidal Sinus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clonidine 75

Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).

Group Type EXPERIMENTAL

Clonidine 75 µg/mL in sacrococcygeal block

Intervention Type DRUG

Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture

Lidocaine

Intervention Type DRUG

3 ml lidocaine 1% is injected at each block site

Pilonidal sinus

Intervention Type PROCEDURE

Removal of pilonidal sinus

Clonidine 150

Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).

Group Type EXPERIMENTAL

Clonidine 150 µg/mL in sacrococcygeal block

Intervention Type DRUG

Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture

Lidocaine

Intervention Type DRUG

3 ml lidocaine 1% is injected at each block site

Pilonidal sinus

Intervention Type PROCEDURE

Removal of pilonidal sinus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clonidine 75 µg/mL in sacrococcygeal block

Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture

Intervention Type DRUG

Clonidine 150 µg/mL in sacrococcygeal block

Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture

Intervention Type DRUG

Lidocaine

3 ml lidocaine 1% is injected at each block site

Intervention Type DRUG

Pilonidal sinus

Removal of pilonidal sinus

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for pilonidal sinus surgery

Exclusion Criteria

* Patients who have allergic reactions to lidocaine
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Makassed General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zoher Naja

Chairperson of Anesthesia and Pain Management Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zoher Naja, MD

Role: PRINCIPAL_INVESTIGATOR

Makassed General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Makassed General Hospital

Beirut, , Lebanon

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Lebanon

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zoher Naja, MD

Role: CONTACT

+9611636000 ext. 6405

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zoher Naja, MD

Role: primary

+9611636000 ext. 6405

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

082015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.